NCT05151016 (LUOMITTOA) is a EARLY_PHASE1 clinical trial of mifepristone in Adenomyosis, sponsored by Women's Hospital School Of Medicine Zhejiang University.

Who is sponsoring NCT05151016?

NCT05151016 is sponsored by Women's Hospital School Of Medicine Zhejiang University.

What drugs are being tested in NCT05151016?

Interventions in NCT05151016: mifepristone, Triptorelin Acetate.

What condition does NCT05151016 study?

NCT05151016 studies Adenomyosis, Mifepristone.

Is NCT05151016 still recruiting?

NCT05151016 is currently status unknown. Last updated 9 December 2021.

Last reviewed 2021-12-09 · How we verify

NCT05151016: LUOMITTOA

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Long-term Use of Mifepristone in the Treatment of Adenomyosis

Status unknown EARLY_PHASE1 Last updated 9 December 2021

What this trial tests

EARLY_PHASE1 trial testing mifepristone in Adenomyosis in 140 participants. Status unknown.

Timeline

1 December 2021

Primary endpoint
31 December 2023

31 December 2023

Quick facts

Lead sponsor	Women's Hospital School Of Medicine Zhejiang University
Phase	EARLY_PHASE1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	140
Start date	1 December 2021
Primary completion	31 December 2023
Estimated completion	31 December 2023
Sites	1 location across China

Drugs / interventions tested

mifepristone (MIFEPRISTONE) — full drug profile →
Triptorelin Acetate — full drug profile →

Conditions studied

Adenomyosis — all drugs for Adenomyosis →
Mifepristone — all drugs for Mifepristone →

Sponsor

Women's Hospital School Of Medicine Zhejiang University

Who can join

Adults 18 to 50, female only, with Adenomyosis or Mifepristone. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The design was a prospective, randomized, positive-control, parallel-group, multicenter clinical trial. The study included a randomized, parallel-group treatment for 24 weeks in 140 subjects from eight hospitals in seven cities across the country who were diagnosed with Adenomyosis and associated symptoms (dysmenorrhea, with or without heavy menstrual flow) , the subjects were randomly assigned to the following two groups: 1. Study Group: mifepristone tablets, 10 mg, 1 tablet daily, taken orally (beginning on the third day of Menstruation) for 24 weeks; 2. Control Group: dafinil (Triptorelin Acetate) , 3.75 mg, first injection on the third day of menstruation, followed by intramuscular injection every 28 days for 24 weeks.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Current Medical Therapy for Adenomyosis: From Bench to Bedside.
Etrusco A, Barra F, Chiantera V, Ferrero S, et al · · 2023 · cited 53× · PMID 37837497 · DOI 10.1007/s40265-023-01957-7

Verify or expand the search:

Other trials of mifepristone

Trials testing the same drug.

NCT02012296 — Enzalutamide and Mifepristone in Treating Patients With Metastatic Hormone Resistant Prostate Cancer · Phase 1, PHASE2 · completed

Other recruiting trials for Adenomyosis

Currently open trials in the same condition.

NCT07455721 — Central Sensitization in Women With Adenomyosis: Prevalence, Risk Factors, and Therapeutic Failure · active not recruiting
NCT07486622 — Transvaginal Electromechanical Fragmentation and Removal of Large Uterus in a Sealed Bag: The First Group of Clinical St · active not recruiting
NCT06572852 — Next-Generation Endometriosis Diagnostics Through Comprehensive Multi-Dimensional Analysis · recruiting
NCT06364592 — Electroacupuncture for Dysmenorrhea Secondary to Adenomyosis · NA · recruiting
NCT06604091 — Cohort Profile：The Shandong Adenomyosis Cohort of Population Undergoing Reproductive Technology (SAart) · active not recruiting

Other Women's Hospital School Of Medicine Zhejiang University trials

Trials by the same sponsor.

NCT07369986 — Immunotherapy for Surgery Avoidance in Vulnerable dMMR Endometrial Cancer · Phase 2 · not yet recruiting
NCT07244965 — Neoadjuvant Ivonescimab Plus Chemotherapy Followed by Concurrent Chemoradiotherapy in High-Risk Locally Advanced Cervica · Phase 2 · not yet recruiting
NCT06561308 — Clinical Efficacy Study of PD-1 Inhibitor Combined With Neoadjuvant Chemotherapy in Advanced Endometrial Cancer · Phase 2 · recruiting
NCT07106853 — Prenatal Cell-free DNA Screening in Pregnancies With Diverse Genetic Risk Profiles Utilizing Targeted and Whole-exome Se · not yet recruiting
NCT07082530 — A RCT of Labor Induction at 39 Weeks in Low - Risk Women in China · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05151016 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Women's Hospital School Of Medicine Zhejiang University
Last refreshed: 9 December 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05151016.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing